Toulouse, FRANCE, Lakeland, UNITED STATES, May 29, 2023, 8:15 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the sole Apoa- I human recombinant in the world, clarifies fundamental points on the establishment of its latest equity financing line, after having received questions from its shareholders and the financial community over the past few days.
The commitment of the company IRIS, subscriber, is key to understanding the choice of ABIONYX Pharma to have decided to use this tool of bonds redeemable in shares. Unlike other players who offer dilutive tools, IRIS is an investor whose head office is in the European Union and whose practices seem to best preserve the interests of ABIONYX Pharma and its shareholders. In particular, IRIS has not yet transferred any securities, requested any guarantee on the assets, or demanded any compensation in the event that the Company does not call for new tranches. ABIONYX Pharma recalls that the next tranches of this line of financing can only be exercised at its initiative.